IP Library Granted Patent US 7,981,675
Granted Patent B2
US 7,981,675 · App. 12/033,998 · Granted Jul 19, 2011

LITAF binding site peptides and methods of using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,981,675
App. No.
12/033,998
Granted
Jul 19, 2011
Kind
B2
Abstract

The invention provides molecules containing nucleic acid sequences for fragments of LPS-induced TNF-α factor (LITAF) and vectors containing these sequences. Also provided are molecules that contain the peptide sequence SQTWREPGAAGSPFHL (SEQ ID NO: 5), or homologs thereof. Such molecules may be useful in the treatment of diseases that relate to the expression of TNF-α, where treatment involves the modulation of this expression. The invention also provides methods for identifying compounds that inhibit or enhance the transcription of TNF-α.

Claims (17)

1. A method for determining the enhancement of LITAF binding to a TNF-α promoter region by a compound comprising:

a) incubating a mixture of the following components:

i) a first molecule comprising SEQ ID NO: 5, wherein said molecule is not full-length LITAF,

ii) a second molecule comprising said TNF-α promoter region, and

iii) said compound;

b) measuring the extent of binding of component i) to component ii) in the absence of component iii);

c) measuring the extent of binding of component i) to component ii) in the presence of component iii); and

d) determining the ratio of step c) to step b), wherein an increase of binding in step c) relative to step b) indicates that said compound enhances the binding of LITAF to said TNF-α promoter region.

2. The method of claim 1 , wherein said binding in steps b) and c) is expressed as a ratio of amount of component i) bound to component ii) to the amount of unbound component i).

3. The method of claim 1 , wherein the incubation mixture of step a) is formed within a cell of a cell culture.

4. The method of claim 1 , wherein the incubation mixture of step a) is formed in the absence of a cell.

5. The method of claim 1 , wherein said TNF-α promoter region comprises nucleotides comprising SEQ ID NO: 4 corresponding to nucleotides -515 to −511 upstream of the transcription start site of the human TNF-α gene.

6. The method of claim 1 , wherein said second molecule is fixed to a solid support.

7. The method of claim 1 , wherein said binding results in the functional activation or repression of said TNF-α promoter region.

8. The method of claim 7 , wherein said TNF-α promoter region is functionally linked to a second nucleic acid sequence encoding a reporter moiety and said binding of step b) results in the expression of said reporter moiety.

9. The method of claim 8 , wherein said reporter moiety is luciferase.

10. The method of claim 8 , wherein said reporter moiety is green fluorescence protein.

Assignments (1)
CONFIRMATORY LICENSE Recorded Sep 11, 2019
From: BOSTON UNIVERSITY MEDICAL CAMPUS
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 050340/0596 →
Continuity (3)
Continuation 10796947 · Mar 10, 2004
Provisional Application 60453302 · Mar 10, 2003
Related Publication 20090215049A1 · Aug 27, 2009